Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)

OBJECTIVES: Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral agent targeting the 3-chymotrypsin–like cysteine protease enzyme (3C-like protease or Mpro) which is a key enzyme of the viral cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This co...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemaitre, Florian, Grégoire, Matthieu, Monchaud, Caroline, Bouchet, Stéphane, Saint-Salvi, Béatrice, Polard, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020499/
https://www.ncbi.nlm.nih.gov/pubmed/35618549
http://dx.doi.org/10.1016/j.therap.2022.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020499/
https://www.ncbi.nlm.nih.gov/pubmed/35618549
http://dx.doi.org/10.1016/j.therap.2022.03.005

Ejemplares similares